Biotech scaled

mRNA vaccines + LNP delivery

mRNA vaccines with LNP delivery have moved from basic science proof-of-concept (Karikó/Weissman 2005) to >13 billion COVID-19 doses and now expanding into personalized cancer vaccines with multi-year survival benefits.

What to watch next

Multi-neoantigen cancer vaccine Phase 3 readouts in 2026, in vivo CAR-T therapies entering pivotal trials, and broader mRNA platform expansion into infectious diseases (influenza, RSV, HIV).

Key sub-ideas & techniques

• Pseudouridine-modified mRNA — Karikó & Weissman's 2005 finding that pseudouridine substitution stops innate-immune sensing made mRNA therapy possible — every approved mRNA product, including the COVID-19 vaccines, uses it. [source]
• Lipid nanoparticle (LNP) delivery — Pieter Cullis's ionizable lipid nanoparticles are the actual delivery vehicle behind mRNA medicine; without LNPs, the RNA degrades before it reaches a cell. [source]
• Personalized cancer vaccines — mRNA-4157/V940 (Moderna/Merck) plus pembrolizumab cut melanoma recurrence by ~49% at 5 years — the first durable evidence that personalized neoantigen mRNA vaccines work. [source]
• In vivo CAR-T via mRNA-LNP — Targeted mRNA-LNPs that engineer CAR-T cells inside the patient — no apheresis, no preconditioning chemo — went from preclinical to clinical (Capstan/AbbVie's CPTX2309) for autoimmune disease. [source]
• Self-amplifying & circular RNA — Self-amplifying mRNA (saRNA) and circular RNA dramatically reduce dose and extend protein expression, enabling lower-dose vaccines and longer-acting therapies; Arcturus's saRNA COVID-19 vaccine is approved in Japan. [source]
• Reduced-reactogenicity LNP-mRNA — Lipid nanoparticle-mRNA formulation engineered to reduce IL-1-mediated adverse reactions while preserving antibody response. [source]
• OspA mRNA-LNP (Lyme) — Nucleoside-modified mRNA-LNP vaccine targeting Borrelia burgdorferi outer surface protein A. [source]
• Personalized neoantigen mRNA cancer vaccines — Patient-specific mRNA vaccines encoding tumor-derived neoantigens, paired with checkpoint inhibitors and standard-of-care chemo, now showing durable Phase 1 benefit and progressing to Phase 3. [source]

Current frontier

• Moderna and Merck's mRNA-4157 personalized cancer vaccine combined with Keytruda sustained 49% reduction in recurrence/death risk in melanoma at 5-year follow-up (announced January 2026). [source]
• In vivo CAR-T cell generation using biodegradable polymer nanoparticles delivering mRNA directly to T cells (published 2026 in Science) achieved B-cell depletion of 95% without external cell engineering. [source]
• BioNTech/Regeneron combination BNT111 showed statistically significant improvement in overall response rate in Phase 2 advanced melanoma trial vs. historical controls. [source]
• Karikó and Weissman's 2005 discovery of pseudouridine incorporation reducing immunogenicity revolutionized mRNA therapy; their work has contributed to >13 billion COVID-19 vaccine doses globally. [source]
• Circular mRNA CAR-T cells generated via PIE platform show superior antitumor efficacy vs. linear mRNA through enhanced cytotoxicity and reduced exhaustion (published 2025-2026). [source]

Key people

• Katalin Karikó Professor of Translational Oncology and Immunology; former Senior Vice-President BioNTech · University of Szeged (Hungary); University of Pennsylvania (adjunct); formerly BioNTech (2013-2022) [source]
• Drew Weissman Roberts Family Professor in Vaccine Research; Director of Penn Institute for RNA Innovation · University of Pennsylvania, Perelman School of Medicine [source]
• Stéphane Bancel Chief Executive Officer · Moderna Therapeutics [source]
• Uğur Şahin Chief Executive Officer (departing end of 2026); Co-founder · BioNTech SE (planning exit); launching new mRNA company with Özlem Türeci [source]
• Pieter Cullis Professor of Biochemistry and Molecular Biology; Director Nanomedicines Research Group; Co-founder Acuitas Therapeutics · University of British Columbia; Acuitas Therapeutics [source]

Startups & labs to watch

• Moderna/Merck cancer vaccine program Moderna Therapeutics & Merck · STARTUP · Funded by Moderna ($10B+ annual R&D) and Merck partnership — Eight Phase 2/3 trials ongoing in melanoma, NSCLC, bladder cancer, renal cancer; Phase 3 readout expected 2026; personalized neoantigen approach shows durable long-term benefit. [source]
• Capstan Therapeutics (AbbVie acquisition) In vivo CAR-T therapy startup (acquired by AbbVie 2025) · STARTUP · Acquired by AbbVie for $2.1B (all-cash, 2025) — Initiated Phase 1 trial for CPTX2309 (anti-CD19 in vivo CAR-T) for autoimmune disease (June 2025); first clinical translation of in vivo mRNA-based CAR-T nanoparticles. [source]
• Uğur Şahin & Özlem Türeci's new mRNA company Next-generation mRNA platform startup · STARTUP · To be spun from BioNTech with proprietary technology transfer — Launching end of 2026 with 'disruptive' next-gen mRNA innovations; receiving mRNA tech from BioNTech; binding agreement expected by June 2026. [source]